Author pages are created from data sourced from our academic publisher partnerships and public sources.
Retrospective drug utilization review and the behavior of Medicaid prescribers: an empirical marginal analysis.
The objectives of this study were to evaluate the effectiveness of drug utilization review (DUR) letter intervention on reducing the cost of medications under Medicaid. The target drugs in this study… Expand
Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.
- J. Guo, J. T. Gibson, D. Gropper, S. Oswald, K. Barker
- The American journal of managed care
- 1 October 1998
OBJECTIVE To determine total direct costs-of-illness and to study the influence of different factors affecting these costs. In addition, we examined each type of service (e.g., hospitalization,… Expand
PCN77 HEALTH SERVICES UTILIZATION AND EXPENDITURES AMONG PROSTATE CANCER PATIENTS WITH AND WITHOUT DEPRESSION IN THE UNITED STATES FROM 2010 TO 2015: A PROPENSITY SCORE-MATCHED CROSS-SECTIONAL STUDY
Trends in The Utilization, Spending, and Prices For Smoking Cessation and Nicotine Replacement Products In US Medicaid Programs: 1991–2015
PGI2 ADVERSE EVENTS OF PROMETHAZINE AND ONDANSETRON IN YOUNG CHILDREN AND WOMEN OF CHILD-BEARING AGE: A PHARMACOVIGILANCE STUDY BASED ON THE FDA ADVERSE EVENT REPORTING SYSTEM
s A69 the warfarin and $10,195 (12,780) in the warfarin and NSAID groups (p < 0.01). CONCLUSIONS: This analysis did not identify a difference in the odds of having a GI bleed when on warfarin or… Expand
Veno-Occlusive Disease (VOD) Associated with Gemtuzumab Ozogamicin (GO) and Inotuzumab Ozogamicin: Analysis of the FDA Adverse Event Reporting System
Metformin in normoglycemic obesity: a systematic review
PMH40 TREATMENT COST AND COMORBIDITIES ASSOCIATED WITH OBESITY AMONG MEDICAID PATIENTS WITH BIPOLAR DISORDER
PCV30 TREND ANALYSIS OF PRICE AND UTILIZATION OF STATIN DRUGS IN U.S. MEDICAID PROGRAMS
Results are expressed as cost per life year gained (LYG). RESULTS: The results for a hypothetical male with a 10-year risk of cardiovascular death of 5% are reported. Compared to no statin the… Expand